New study links Ozempic-like drugs to slightly higher hair loss risk

A BMJ study found a small rise in non-scarring hair loss among people using GLP-1 drugs. Doctors say the overall risk remains low and patients should not stop treatment without medical advice.

In Short

• Researchers analysed diabetes records comparing GLP-1 medicines with other drug classes
• Absolute hair loss risk remained low at three to nine cases annually
• Experts said the study shows association, not direct causation, behind shedding

The promise of dramatic weight loss has made drugs such as Ozempic, Wegovy and Mounjaro household names. But as millions embrace these medications, attention is increasingly shifting from shrinking waistlines to unexpected cosmetic side effects – from the much-discussed “Ozempic face” to hair thinning.

A major new study now suggests there is a small but measurable increase in the risk of hair loss among people taking GLP-1-based drugs.

The findings, however, come with an important caveat: the overall risk remains low, and experts say patients should not panic or stop treatment without medical advice.

The study, published in The BMJ, analysed electronic health records of adults with type 2 diabetes and compared those taking GLP-1 receptor agonists with people using other classes of diabetes medications.

Researchers found users of GLP-1 based drugs had a 37% higher risk of developing non-scarring hair loss than those taking SGLT-2 inhibitors and a 68% higher risk compared with DPP-4 inhibitors.

Even so, the absolute risk was relatively small, at around three to nine cases per 1,000 people annually.

The findings arrive at a time when GLP-1-based medicines such as semaglutide and tirzepatide, that work by mimicking gut hormones, slowing digestion and reducing appetite, have rapidly gained popularity in India.

Initially prescribed for type 2 diabetes, these drugs are now increasingly sought after for obesity management, driven by rising obesity rates, growing awareness of metabolic health and widespread social media attention. They are also being studied and used for treating various other conditions.

Recently, Wegovy, a higher dose of semaglutide by Danish drugmaker Novo Nordisk – was approved in India by the Central Drugs Standard Control Organisation (CDSCO) for treating non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a severe type of fatty liver disease.

WHAT THE STUDY FOUND

The researchers stressed that the study establishes an association rather than proving that the medicines directly cause hair loss. Most cases involve non-scarring alopecia, meaning the hair follicles remain intact and regrowth is generally possible.

Doctors say the findings fit with what is already known about rapid weight loss. Temporary hair shedding, known as telogen effluvium, can occur after significant physical stress, including sudden weight reduction, severe calorie restriction or nutritional deficiencies.

Dr Aparna Santhanam, dermatologist at PD Hinduja Hospital & Medical Research Centre in Mumbai said the study should reassure rather than alarm patients.

“Hair loss is one of the side effects that patients worry about most, so this study is reassuring in many ways,” she said, noting that while there may be a small increase in temporary hair shedding with GLP-1 medicines, “the overall risk remains low.”

Delhi-based hair transplant surgeon and founder of The Crown clinic Dr Mayank Singh explained that the medications may not be the only factor involved.

Rapid weight loss, lower calorie intake and deficiencies of nutrients such as protein, iron and zinc are all recognised triggers of temporary hair shedding and are commonly seen in dermatology irrespective of how weight loss occurs, he underlined.

WHY HAIR FALLS

Dr Singh says the most likely explanation is telogen effluvium, a temporary disruption of the hair growth cycle that pushes more hair follicles into the shedding phase.

Hair loss typically becomes noticeable two to four months after substantial weight loss begins. This can happen because of severe calorie restriction, nutritional deficiencies, hormonal shifts and the physical stress placed on the body during rapid weight reduction.

These factors, rather than the drugs themselves, are considered the most probable triggers in many patients.

Dermatologists emphasise that telogen effluvium is usually self-limiting, with hair regrowth occurring naturally once the underlying trigger is addressed. Patients experiencing unusual hair loss are advised to undergo evaluation for nutritional deficiencies, thyroid disorders and other possible causes before attributing the problem solely to the medication.

Comprehensive blood tests assessing protein levels, iron, vitamin D, vitamin B12, zinc and thyroid function can help identify deficiencies that may worsen hair shedding. Maintaining a balanced diet with adequate protein and micronutrients is also important while losing weight.

BENEFITS STILL OUTWEIGH RISKS

Despite the new findings, specialists caution against discontinuing GLP-1 medications without consulting a doctor. These drugs remain among the most effective treatments available for improving blood sugar control, promoting sustained weight loss and reducing the risk of obesity-related complications.

Dr Santhanam advised patients not to make treatment decisions based solely on concerns about hair fall.

“The key message is not to panic or stop treatment on your own,” she said. If hair shedding becomes noticeable, patients should seek medical advice early so nutritional deficiencies and other contributing factors can be identified and corrected.

She added that, for most people, the proven benefits of GLP-1 based medicines in improving diabetes control, reducing weight and enhancing overall metabolic health continue to outweigh what is generally a manageable and temporary side effect.

- Ends